Clinical Trials

JERUSALEM, Nov. 15, 2017 /PRNewswire/ — Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announced its third quarter 2017 financial results and provided a corporate update. “The third quarter was truly transformational for Intec Pharma.  We advanced our clinical development programs and are continuing to move forward with our pivotal Phase 3 trial in Parkinson’s […]

by

(MENAFN Editorial) VANCOUVER, British Columbia, Nov. 16, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSX-V:) (“Harvest One”) through its wholly owned Swiss Subsidiary Satipharm AG (“Satipharm”) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by PhytoTech Therapeutics (“PTL”) in Israel using Satipharm’s proprietary GelpellR technology have been published. The […]

by

VANCOUVER, British Columbia, Nov. 16, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSX-V:HVST) (“Harvest One“) through its wholly owned Swiss Subsidiary Satipharm AG (“Satipharm“) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by PhytoTech Therapeutics (“PTL“) in Israel using Satipharm’s proprietary GelpellR technology have been published. The article “Single-Dose […]

by

JERUSALEM, Nov. 15, 2017 /PRNewswire/ — Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announced its third quarter 2017 financial results and provided a corporate update. “The third quarter was truly transformational for Intec Pharma.  We advanced our clinical development programs and are continuing to move forward with our pivotal Phase 3 trial in Parkinson’s […]

by

VANCOUVER, British Columbia, Nov. 16, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSX-V:HVST) (“Harvest One“) through its wholly owned Swiss Subsidiary Satipharm AG (“Satipharm“) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by PhytoTech Therapeutics (“PTL“) in Israel using Satipharm’s proprietary GelpellR technology have been published. The article “Single-Dose […]

by

“The third quarter was truly transformational for Intec Pharma.  We advanced our clinical development programs and are continuing to move forward with our pivotal Phase 3 trial in Parkinson’s Disease. Additionally, we enhanced our organizational capabilities to fully develop and commercialize the Accordion Pill, taking us another step closer to our goal of becoming a […]

by

Perth, Nov 16, 2017 AEST (ABN Newswire) – MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or “the Company”) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by MMJ’s wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd (“PTL”) have been published. The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation […]

by

DEVON, Pa., Nov. 14, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today reported financial results for the third quarter ended September 30, 2017 and provided an overview of recent operational highlights. “We announced important data during the third quarter, […]

by

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSXV:HVST) (“Harvest One” or the “Company“) through its wholly owned Swiss subsidiary, Satipharm AG (“Satipharm“), is pleased to advise that it’s Melbourne-based distribution partner, HL Pharma Pty Ltd (“HL Pharma”), has commenced distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia. […]

by

DEVON, Pa., Nov. 14, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today reported financial results for the third quarter ended September 30, 2017 and provided an overview of recent operational highlights. “We announced important data during the third quarter, […]

by

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSXV:HVST) (“Harvest One” or the “Company“) through its wholly owned Swiss subsidiary, Satipharm AG (“Satipharm“), is pleased to advise that it’s Melbourne-based distribution partner, HL Pharma Pty Ltd (“HL Pharma”), has commenced distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia. […]

by

Dr. Sue Sisley, a medical marijuana researcher, speaks at the Arizona Secretary of State’s Office Wednesday, April 14, 2010 at the Capitol in Phoenix. (AP Photo/Matt York) When the U.S. Food and Drug Administration (FDA) warned cannabidiol producers against making medical claims about cannabis products, it seemed par for the course for any federal agency. Cannabis […]

by

​Earlier this week, the U.S. Food and Drug Administration (FDA or the Agency) issued Warning Letters to four companies – Greenroads Health, Natural Alchemist, That’s Natural! Marketing and Consulting, and Stanley Brothers Social Enterprises LLC – citing unsubstantiated claims related to more than 25 different products sold online that allegedly contain cannabidiol (CBD), a component […]

by